G-CURE makes your cardiovascular drug a success by building on decades of cardiovascular research experience and utilizing our vast network of experts in the field of drug development.
Our services
Creative ideas and cutting edge technology shape the treatments of tomorrow. Our research ranges from basic and translational science to multicentre clinical trials. G-Cure’s ‘Continuum for Drug Development in Heart Diseases’ is focused on different aspects of development. You can find these below and select the ones which interest you the most.
Blood Sampling in Cohorts
UMCG Cardiology and G-Cure have access to many biobanks with biomaterials from very well phenotyped patients in the field of heart failure, atrium fibrillation and ischemic heart diseases.
“UMCG Cardiology and G-Cure have access to many biobanks with biomaterials”
Omics Bio-informatic Analyses
G-Cure has experienced staff with an outstanding track-record in the field of bio-informatic analyses. Integrating multiomics data using state-of-the art artificial intelligenc techniques we are able to identify specific pathophysiological pathways that are activated or de-activated in specific patient populations. These pathways help to identify treatment targets for specific populations of patients with heart failure, atrium fibrillation and ischemic heart diseases.
Mechanistic Targets for Therapy
Ourr bio-informatic analyses on multi-omics data from patients with heart failure has already yielded several potential novel treatment targets. For example, using a systems biology approach, integrating genetic, transcriptomic and proteomic data yielded pathways that were related to decreased activation of the cardioprotective ERBB2 receptor, which can be modified by neuregulin. Recently, several neuregulin associated drug development programs have started.
Molecule Development
We have collaborations with the Groningen University Department of Chemistry and Molecular Pharmacology that provide services in the broad range from hit generation, lead optimization until integrated drug discovery.
Pre-Clinical Studies
We conduct research in the established experimental laboratory and cardiology department of the UMCG, an acclaimed academic medical center.
Phase I/Ib Clinical Studies
Phase I and Ib studies are conducted in close collaboration with ICON International. ICON and UMCG have a joined Clinical Research Unit (CRU) on the premises of the UMCG. ICON and the department of Cardiology have extensive experience in conducting fast track phase 1 safety and tolerability studies, with the addition of small groups of patients for early efficacy evaluation.
Phase IIa/IIb Clinical Studies
Cardio Research, the dedicated research unit of the department of Cardiology, has over 15 years of experience in conducting Phase 2a/b studies. In collaboration with the UMCG we can offer a wide array of (invasive) techniques to add sophisticated scientific data to your drug profile. Also, overnight confinement of patients is a service we can offer.
Phase III Clinical Studies
Cardio Research, the dedicated research unit of the department of Cardiology, has over 25 years of experience in conducting Phase 3 studies.
